KR20110063457A - 대상에서의 지속적 치료 약물 농도 달성을 위한 조성물 및 방법 - Google Patents

대상에서의 지속적 치료 약물 농도 달성을 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20110063457A
KR20110063457A KR1020117005982A KR20117005982A KR20110063457A KR 20110063457 A KR20110063457 A KR 20110063457A KR 1020117005982 A KR1020117005982 A KR 1020117005982A KR 20117005982 A KR20117005982 A KR 20117005982A KR 20110063457 A KR20110063457 A KR 20110063457A
Authority
KR
South Korea
Prior art keywords
prodrug
days
administering
administration
irinotecan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117005982A
Other languages
English (en)
Korean (ko)
Inventor
마이클 에이 엘든
시바니 에스 해리트
탐라 엘 바커
Original Assignee
넥타르 테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥타르 테라퓨틱스 filed Critical 넥타르 테라퓨틱스
Publication of KR20110063457A publication Critical patent/KR20110063457A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
KR1020117005982A 2008-09-23 2009-09-23 대상에서의 지속적 치료 약물 농도 달성을 위한 조성물 및 방법 Ceased KR20110063457A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US9951608P 2008-09-23 2008-09-23
US61/099,516 2008-09-23
US10693108P 2008-10-20 2008-10-20
US61/106,931 2008-10-20
US17343309P 2009-04-28 2009-04-28
US61/173,433 2009-04-28

Publications (1)

Publication Number Publication Date
KR20110063457A true KR20110063457A (ko) 2011-06-10

Family

ID=41268391

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117005982A Ceased KR20110063457A (ko) 2008-09-23 2009-09-23 대상에서의 지속적 치료 약물 농도 달성을 위한 조성물 및 방법

Country Status (21)

Country Link
US (3) US8906353B2 (enExample)
EP (1) EP2349346B1 (enExample)
JP (3) JP2012503602A (enExample)
KR (1) KR20110063457A (enExample)
CN (1) CN102164617A (enExample)
AU (1) AU2009297091B2 (enExample)
CA (1) CA2736939C (enExample)
CY (1) CY1122208T1 (enExample)
DK (1) DK2349346T3 (enExample)
ES (1) ES2744975T3 (enExample)
HR (1) HRP20192120T1 (enExample)
HU (1) HUE047352T2 (enExample)
IL (1) IL211888A (enExample)
LT (1) LT2349346T (enExample)
MX (1) MX2011003063A (enExample)
PL (1) PL2349346T3 (enExample)
PT (1) PT2349346T (enExample)
RS (1) RS59607B1 (enExample)
SI (1) SI2349346T1 (enExample)
SM (1) SMT201900609T1 (enExample)
WO (1) WO2010036335A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59607B1 (sr) 2008-09-23 2020-01-31 Nektar Therapeutics Metod metronomskog doziranja kamptotecinskih prolekova (npr. peg-irinotekan)
WO2012137225A1 (en) * 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
AU2013352223B2 (en) * 2012-11-28 2019-07-18 Nektar Therapeutics Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor
EP3258913A1 (en) * 2015-02-17 2017-12-27 Mallinckrodt Nuclear Medicine LLC Modified docetaxel liposome formulations and uses thereof
CN114224865A (zh) 2016-06-02 2022-03-25 因华生技制药股份有限公司 供癌症医疗的节拍式口服吉西他宾
CN106539557A (zh) * 2016-10-08 2017-03-29 西安交通大学 一种基于恒速静脉输入的药代动力学参数的测定方法
MX2021003116A (es) * 2018-09-17 2021-05-14 Childrens Hospital Philadelphia Profarmacos macromoleculares a base de polimero.
US20240156808A1 (en) * 2021-02-23 2024-05-16 Edison Oncology Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases
CN115317486B (zh) * 2022-08-17 2024-04-19 南昌大学 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
TW438775B (en) 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
EP0932399B1 (en) 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
JP2002542304A (ja) 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド 酵素的に活性化された重合薬物接合体
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
DK1259562T3 (da) 1999-12-22 2006-04-18 Nektar Therapeutics Al Corp Sterisk hindrede derivater af vandoplöselige polymerer
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
DK1301810T3 (da) 2000-07-21 2009-01-26 Schlumberger Services Petrol Kernemagnetiske resonansfremgangsmåder til at uddrage information om et fluidum i en klippe
JP2004514701A (ja) 2000-11-30 2004-05-20 ネクター　セラピューティクス　エーエル，コーポレイション トリアジン誘導体の水溶性ポリマー複合体
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7401013B2 (en) 2001-10-15 2008-07-15 Lockheed Martin Corporation Method to optimize test data
MXPA04004026A (es) 2001-10-29 2004-07-08 Nektar Therapeutics Al Corp Conjugados polimericos de inhibidores de la proteina quinasa c.
ATE359829T1 (de) 2001-10-30 2007-05-15 Nektar Therapeutics Al Corp Wasserlösliche polymerkonjugate von retinoesäure
JP2005517648A (ja) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
RU2004139090A (ru) 2002-06-06 2005-06-10 Юниверсити Оф Вашингтон (Us) Способы применения соединений, подобных артемизинину, для профилактики или задержки возникновения злокачественных опухолей
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
KR20120104412A (ko) 2002-09-06 2012-09-20 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
KR20120073370A (ko) * 2003-09-17 2012-07-04 넥타르 테라퓨틱스 다분지형 고분자 전구약물
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
EP1989212B1 (en) 2006-02-17 2013-06-19 Cascade Prodrug Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
KR20090108082A (ko) 2007-02-09 2009-10-14 엔존 파마슈티컬즈, 인코포레이티드 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법
CN101199857B (zh) 2007-12-12 2011-04-13 中国药科大学 mPEG-PLA-喜树碱类药物的结合物
RS59607B1 (sr) 2008-09-23 2020-01-31 Nektar Therapeutics Metod metronomskog doziranja kamptotecinskih prolekova (npr. peg-irinotekan)

Also Published As

Publication number Publication date
WO2010036335A1 (en) 2010-04-01
HRP20192120T1 (hr) 2020-02-21
AU2009297091B2 (en) 2015-03-05
ES2744975T3 (es) 2020-02-27
JP2012503602A (ja) 2012-02-09
MX2011003063A (es) 2011-04-21
US20150087668A1 (en) 2015-03-26
EP2349346A1 (en) 2011-08-03
PT2349346T (pt) 2019-10-24
IL211888A (en) 2015-08-31
IL211888A0 (en) 2011-06-30
PL2349346T3 (pl) 2020-03-31
SI2349346T1 (sl) 2019-12-31
US10525051B2 (en) 2020-01-07
JP2016216510A (ja) 2016-12-22
RS59607B1 (sr) 2020-01-31
US20180028525A1 (en) 2018-02-01
EP2349346B1 (en) 2019-08-28
CN102164617A (zh) 2011-08-24
CA2736939C (en) 2021-09-14
JP6076317B2 (ja) 2017-02-08
AU2009297091A1 (en) 2010-04-01
CY1122208T1 (el) 2020-11-25
HUE047352T2 (hu) 2020-04-28
US20110269789A1 (en) 2011-11-03
CA2736939A1 (en) 2010-04-01
US8906353B2 (en) 2014-12-09
JP2015034180A (ja) 2015-02-19
LT2349346T (lt) 2019-09-25
US9801873B2 (en) 2017-10-31
SMT201900609T1 (it) 2020-01-14
DK2349346T3 (da) 2019-10-07

Similar Documents

Publication Publication Date Title
US10525051B2 (en) Compositions and methods for achieving sustained therapeutic drug concentrations in a subject
Zhao et al. Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy
Venditto et al. Cancer therapies utilizing the camptothecins: a review of the in vivo literature
ES2770733T3 (es) Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas
JP7703001B2 (ja) 相乗的がん治療
WO2013044219A1 (en) Methods of treating cancers with therapeutic nanoparticles
CA2939165A1 (en) A cdp-camptothecin conjugate, particle or composition and uses thereof
US20220023290A1 (en) Therapeutic dendrimer
KR20160024985A (ko) 암 치료를 위한 도세탁셀 중합체성 나노입자
WO2014084378A1 (ja) 環状ｒｇｄ配列含有ペプチドを含む抗癌剤
AU2019446285B2 (en) Pharmaceutical compositions containing mixed polymeric micelles
CN102159190A (zh) 化疗剂的口服制剂
KR101678881B1 (ko) 부작용을 가지지 않는 항암제
HK1155083B (en) Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)
HK1155083A (en) Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)
AU2013205079B2 (en) Treatment of cancer
HK1161084A (en) Oral formulations of chemotherapeutic agents
HK1214145B (en) Anticancer agent having no side effects

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110315

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140826

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160112

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161124

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160112

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20161124

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160708

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20140826

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170102

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20161216

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20161124

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160708

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160112

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20140826

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20170403

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20170102

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20161124

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20181017

Appeal identifier: 2017101001603

Request date: 20170403

J301 Trial decision

Free format text: TRIAL NUMBER: 2017101001603; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20170403

Effective date: 20181017

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20181017

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20170403

Decision date: 20181017

Appeal identifier: 2017101001603

PJ2001 Appeal

Patent event date: 20181017

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190627

Appeal identifier: 2018201009329

Request date: 20181214

PJ1302 Judgment (patent court)

Patent event date: 20190628

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20181214

Decision date: 20190627

Appeal identifier: 2018201009329

Appeal kind category: Appeal against decision to decline refusal